Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Masked (Evaluator), Controlled, Prospective Study Evaluating the Effectiveness and Safety of the Tixel® Medical Device, Versus LipiFlow® in the Treatment of Meibomian Gland Dysfunction

NCT05162261 is registered in ClinicalTrials.gov with Novoxel Ltd. as lead sponsor.

NCT NCT05162261
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05162261 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Masked (Evaluator), Controlled, Prospective Study Evaluating the Effectiveness and Safety of the Tixel® Medical Device, Versus LipiFlow® in the Treatment of Meibomian Gland Dysfunction
Lead sponsor
Novoxel Ltd.
Phase
Not applicable
Overall status
Completed
Start date
September 19, 2022
Completion date
September 28, 2023
Enrollment
109 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

dry eye, dry eye syndromes, meibomian gland dysfunction